Modulation_NN of_IN Human_NP Immunodeficiency_NN Virus_NP (HIV)-Specific_NP Immune_NP Response_NP by_IN Using_VBG Efavirenz_NP ,_, Nelfinavir_NP ,_, and_CC Stavudine_NP in_IN a_DT Rescue_NP Therapy_NN Regimen_NP for_IN HIV-Infected_NP ,_, Drug-Experienced_NP Patients_NPS Analysis_NP of_IN the_DT virologic_JJ and_CC immunomodulatory_JJ effects_NNS of_IN an_DT association_NN of_IN efavirenz_NP (_( EFV_NP )_) ,_, nelfinavir_NP (_( NFV_NP )_) ,_, and_CC stavudine_NP (_( d4T_NP )_) was_VBD performed_VBN in_IN 18_CD human_JJ immunodeficiency_NN virus_NN (HIV)-infected_JJ and_CC highly_RB active_JJ antiretroviral_JJ therapy_NN (HAART)-experienced_JJ patients_NNS who_WP failed_VBD multiple_JJ therapeutic_JJ protocols_NNS ._SENT Patients_NNS (_( <500_CD4+ 10,000_CD HIV_NP copies/ml_NN )_) were_VBD nonnucleoside_JJ reverse_JJ transcriptase_NN inhibitor_NN (NNRTI)-naive_NN and_CC were_VBD treated_VBN for_IN 10_CD months_NNS with_IN EFV_NP (_( 600_CD mg/day_NN )_) in_IN association_NN with_IN NFV_NP (_( 750_CD mg_NN three_CD times_NNS daily_RB )_) and_CC d4T_JJ (_( 30_CD or_CC 40_CD mg_NN twice_RB daily_JJ )_) ._SENT Measurement_NN of_IN HIV_NP peptide-_NN and_CC mitogen-stimulated_JJ production_NN of_IN interleukin-2_NN (_( IL-2_NP )_) ,_, gamma_NN interferon_NN (_( IFN-gamma_NP )_) ,_, IL-4_NN ,_, and_CC IL-10_NP as_RB well_RB as_IN quantitation_NN of_IN mRNA_NN for_IN the_DT same_JJ cytokines_NNS in_IN unstimulated_JJ peripheral_JJ blood_NN mononuclear_JJ cells_NNS were_VBD performed_VBN at_IN baseline_NN and_CC 2_CD weeks_NNS (_( t1_JJ )_) ,_, 2_CD months_NNS (_( t2_NN )_) ,_, and_CC 10_CD months_NNS (_( t3_NN )_) into_IN therapy_NN ._SENT The_DT results_NNS showed_VBD that_IN HIV-specific_NP (_( but_CC not_RB mitogen-stimulated_JJ )_) IL-2_NP and_CC IFN-gamma_NP production_NN was_VBD augmented_JJ and_CC IL-10_JJ production_NN was_VBD reduced_VBN in_IN patients_NNS who_WP received_VBD EFV_NP ,_, NFV_NP ,_, and_CC d4T_NN ._SENT Therapy_NN was_VBD also_RB associated_VBN with_IN a_DT reduction_NN in_IN HIV_NP RNA_NP in_IN plasma_NN and_CC an_DT increase_NN in_IN CD4+_NP cell_NN count_NN ._SENT These_DT changes_NNS occurred_VBD in_IN the_DT first_JJ year_NN of_IN therapy_NN (_( t2_NN and_CC t3_NN )_) and_CC were_VBD confirmed_VBN by_IN quantitation_NN of_IN cytokine-specific_JJ mRNA_NN ._SENT Therapy_NN with_IN EFV_NP ,_, NFV_NP ,_, and_CC d4T_NN increases_NNS HIV-specific_JJ type_NN 1_CD cytokine_NN production_NN as_RB well_RB as_IN CD4_NP counts_VBZ and_CC reduces_VBZ plasma_NN viremia_NNS ._SENT This_DT therapeutic_JJ regimen_NN may_MD be_VB considered_VBN for_IN use_NN in_IN cases_NNS of_IN advanced_JJ HIV_NP infection_NN ._SENT The_DT progression_NN of_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) infection_NN to_TO AIDS_NP is_VBZ associated_VBN with_IN increasing_VBG HIV_NP viral_JJ load_NN and_CC qualitative_JJ and_CC quantitative_JJ defects_NNS affecting_VBG CD4_NP T_NN lymphocytes_NNS and_CC cell-mediated_JJ immunity_NN ._SENT Drugs_NNS designed_VBN as_IN therapeutic_JJ tools_NNS against_IN HIV_NP infection_NN should_MD thus_RB ideally_RB be_VB capable_JJ of_IN stimulating_VBG cell-mediated_JJ immunity_NN and_CC reducing_VBG HIV_NP viremia_NN ._SENT Nevertheless_RB ,_, whereas_IN highly_RB active_JJ antiretroviral_JJ therapy_NN (_( HAART_NP )_) can_MD achieve_VB suppression_NN of_IN HIV_NP viremia_NN in_IN HIV-infected_JJ individuals_NNS ,_, the_DT efficacy_NN of_IN these_DT antiretroviral_JJ therapies_NNS in_IN reconstituting_VBG immune_JJ function_NN has_VBZ been_VBN less_RBR dramatic_JJ ._SENT Nonnucleoside_JJ reverse_JJ transcriptase_NN inhibitors_NNS (_( NNRTI_NP )_) ,_, nucleoside_NN reverse_NN transcriptase_NN inhibitors_NNS (_( NRTI_NP )_) ,_, and_CC protease_NN inhibitors_NNS (_( PI_NP )_) are_VBP currently_RB used_VBN in_IN the_DT treatment_NN of_IN HIV-1_JJ infection_NN (_( reviewed_VBN in_IN references_NNS ,_, ,_, ,_, and_CC )_) ._SENT Efavirenz_NP (_( EFV_NP )_) is_VBZ an_DT NNRTI_NP which_WDT in_IN combination_NN with_IN other_JJ antiretroviral_JJ drugs_NNS induces_VBZ viral_JJ suppression_NN as_RB well_RB as_IN increases_NNS in_IN CD4_NP counts_VBZ ._SENT Treatment_NN with_IN EFV_NP may_MD be_VB provided_VBN on_IN a_DT once-a-day_NN ,_, no-food-interaction_NN schedule_NN that_WDT makes_VBZ its_PP$ compliance_NN higher_RBR than_IN that_DT of_IN other_JJ drugs_NNS ._SENT Furthermore_RB ,_, although_IN cross-resistance_NN within_IN the_DT NNRTI_NP class_NN is_VBZ extensive_JJ and_CC the_DT presence_NN of_IN point_NN mutations_NNS (_( K103N_NP ,_, Y181C_NP )_) may_MD exclude_VB the_DT efficacy_NN of_IN the_DT entire_JJ class_NN ,_, there_EX is_VBZ some_DT evidence_NN that_IN EFV_NP may_MD retain_VB full_JJ activity_NN against_IN more_JJR than_IN 25_CD %_NN of_IN Y181C-mutated_JJ viruses_NNS ,_, even_RB though_IN an_DT NNRTI_NP sequential_JJ treatment_NN is_VBZ still_RB not_RB recommended_VBN by_IN international_JJ guidelines_NNS ._SENT Because_IN of_IN these_DT interesting_JJ pharmacokinetic_JJ properties_NNS we_PP decided_VBD to_TO evaluate_VB the_DT potential_JJ usefulness_NN of_IN this_DT compound_NN in_IN advanced_JJ HIV_NP infection_NN ._SENT Therefore_RB ,_, we_PP investigated_VBD immune_JJ and_CC virologic_JJ parameters_NNS in_IN patients_NNS undergoing_VBG therapy_NN with_IN an_DT EFV-containing_NP regimen_NN ._SENT In_IN particular_JJ ,_, because_IN progression_NN to_TO AIDS_NP and_CC loss_NN of_IN CD4+_NP T_NN cells_NNS is_VBZ associated_VBN with_IN the_DT impairment_NN of_IN type_NN 1_CD cytokine_NN production_NN ,_, we_PP verified_VBD that_IN EFV-containing_JJ antiviral_JJ therapies_NNS stimulated_VBN cell-mediated_JJ immunity_NN and_CC a_DT type_NN 1_CD cytokine_NN profile_NN ._SENT Patients_NNS ._SENT |_SYM Eighteen_JJ HIV-infected_JJ patients_NNS were_VBD randomly_RB selected_VBN among_IN those_DT enrolled_VBN in_IN a_DT study_NN to_TO evaluate_VB the_DT efficacy_NN of_IN an_DT EFV-_NP ,_, nelfinavir_NN (NFV)-_NN ,_, and_CC stavudine_NP (d4T)-based_JJ rescue_NN therapy_NN ._SENT The_DT only_JJ selection_NN bias_NN was_VBD the_DT patient_NN 's_POS willingness_NN to_TO be_VB included_VBN in_IN the_DT study_NN ._SENT These_DT patients_NNS had_VBD failed_VBN previous_JJ combination_NN therapies_NNS (_( including_VBG multiple_JJ nucleoside_NN analogues_NNS and_CC at_IN least_JJS one_CD PI_NNS )_) and_CC they_PP (_( i_NP )_) were_VBD failing_VBG the_DT current_JJ PI-containing_NP therapy_NN ,_, (_( ii_NNS )_) were_VBD naive_JJ for_IN NNRTIs_NP ,_, (_( iii_NP )_) had_VBD never_RB received_VBN NFV_NP ,_, (_( iv_NP )_) had_VBD no_DT evidence_NN of_IN active_JJ HIV-related_JJ infections_NNS or_CC neoplasms_NNS ;_: and_CC (_( v_NN )_) had_VBD never_RB been_VBN treated_VBN with_IN immunomodulants_NNS (_( e.g._FW ,_, interleukin-2_NN [_SYM IL-2_NP ]_SYM )_) ._SENT EFV_NP was_VBD administered_VBN at_IN a_DT dose_NN of_IN 600_CD mg_NN daily_JJ at_IN bedtime_NN ,_, NFV_NP was_VBD given_VBN at_IN 750_CD mg_NN every_DT 8_CD h_NN ,_, and_CC d4T_NN was_VBD given_VBN at_IN 30_CD or_CC 40_CD mg_NN ,_, depending_VBG on_IN body_NN weight_NN ,_, twice_RB daily_JJ ._SENT Blood_NN sample_NN collection_NN ._SENT |_SYM Whole_NP blood_NN was_VBD collected_VBN by_IN venipuncture_NN immediately_RB before_IN treatment_NN (_( t0_NN )_) and_CC 2_CD weeks_NNS (_( t1_JJ )_) as_IN well_RB as_IN 2_CD months_NNS (_( t2_NN )_) and_CC 10_CD months_NNS (_( t3_NN )_) after_IN the_DT start_NN of_IN therapy_NN in_IN EDTA_NP Vacutainer_NP tubes_NNS (_( Becton_NP Dickinson_NP &_CC Co._NP ,_, Rutherford_NP ,_, N.J._NP )_) ._SENT Peripheral_JJ blood_NN mononuclear_JJ cells_NNS (_( PBMC_NP )_) were_VBD separated_VBN on_IN lymphocyte_NN separation_NN medium_NN (_( Organon_NP Teknika_NP Corp._NP ,_, Durham_NP ,_, N.C._NP )_) and_CC washed_VBN twice_RB in_IN phosphate-buffered_JJ saline_NN ,_, and_CC the_DT number_NN of_IN viable_JJ leukocytes_NNS was_VBD determined_VBN by_IN trypan_JJ blue_JJ exclusion_NN ._SENT PBMC_NP were_VBD resuspended_VBN in_IN RPMI_NP 1640_CD (_( Sigma_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) plus_CC 2_CD %_NN AB_NP serum_NN (_( Sigma_NP )_) ._SENT All_DT experiments_NNS were_VBD performed_VBN using_VBG cryopreserved_JJ PBMC_NN ._SENT Antigen-_NN and_CC mitogen-stimulated_JJ cytokine_NN production_NN ._SENT |_SYM Gamma_NP interferon_NN (_( IFN-gamma_NP )_) ,_, IL-2_NP ,_, IL-4_NN ,_, and_CC IL-10_NP production_NN by_IN PBMC_NP was_VBD determined_VBN by_IN culturing_VBG 3_CD x_SYM 106_CD PBMC_NN per_IN well_RB in_IN 24-well_JJ LINBRO_NP plates_NNS (_( Flow_NP Laboratories_NP ,_, Inc._NP )_) (_( 37C_NP ;_: 7_CD %_NN CO2_NN )_) ._SENT PBMC_NP were_VBD unstimulated_VBN or_CC stimulated_VBN with_IN phytohemagglutinin_NN (_( PHA_NP )_) (_( M_NP form_NN ;_: Sigma_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) (_( final_JJ dilution_NN ,_, 1:100_CD )_) for_IN 48_CD h_NN or_CC a_DT pool_NN of_IN five_CD synthetic_JJ peptides_NNS from_IN the_DT gp160_JJ envelope_NN (_( Env_NP )_) of_IN HIV_NP type_NN 1_CD (_( HIV-1_NP )_) (_( 2.5_CD mM_NP final_JJ concentration_NN )_) for_IN 5_CD days_NNS ._SENT The_DT following_VBG peptides_NNS were_VBD utilized_VBN :_: T1_NP (_( KQIINMWQEVGKAMYA_NP )_) ,_, HIV-1/IIIb_NP Env_NP amino_NN acid_NN residues_NNS 428_CD to_TO 443_CD ;_: T2_NP (_( HEDIISLWDQSLK_NP )_) ,_, HIV-1/IIIb_NP Env_NP amino_NN acid_NN residues_NNS 112_CD to_TO 124_CD ;_: TH4.1_NP (_( DRVIEVVQGAYRAIR_NP )_) ,_, HIV-1/IIIb_NP Env_NP amino_NN acid_NN residues_NNS 834_CD to_TO 848_CD ;_: p18-IIIb_NP (_( RIQRGPGRAFVTIGK_NP )_) ,_, HIV-1/III_NP IIIB_NP Env_NP amino_NN acid_NN residues_NNS 315_CD to_TO 329_CD ;_: and_CC p18-MN_JJ (_( RIHIGPGRAFYTTKN_NP )_) ,_, HIV-1_NP (_( MN_NP )_) Env_NP region_NN homologous_JJ to_TO p18-IIIB_NN ._SENT Cytokine_NP production_NN was_VBD evaluated_VBN in_IN the_DT supernatants_NNS with_IN commercially_RB available_JJ enzyme-linked_JJ immunosorbent_JJ assays_NNS (_( Endogen_NP ,_, Woburn_NP ,_, Mass._NP )_) ._SENT RNA_NP extraction_NN ._SENT |_SYM RNA_NP was_VBD extracted_VBN from_IN unstimulated_JJ lymphocytes_NNS with_IN the_DT acid_JJ guanidium_NN thiocyanate-phenol-chloroform_NN method_NN and_CC dissolved_VBN in_IN RNase-free_JJ water_NN ;_: purity_NN was_VBD determined_VBN by_IN spectrophotometry_NN ._SENT Genomic_NP DNA_NP contamination_NN was_VBD removed_VBN by_IN RNase-free_NP DNase_NP (_( RQ1_NP DNase_NP ;_: Promega_NP ,_, Madison_NP ,_, Wis._NP )_) ._SENT Reverse_JJ transcription_NN (_( RT_NP )_) ._SENT |_SYM One_CD microgram_NN of_IN RNA_NP was_VBD reverse_RB transcribed_VBN into_IN first-strand_NN cDNA_NN in_IN a_DT 20-mul_JJ final_JJ volume_NN containing_VBG 1_CD mM_NP random_JJ hexanucleotide_NN primers_NNS ,_, 1_CD mM_NP oligo(dT)_NN ,_, and_CC 200_CD U_NN of_IN Moloney_NP murine_JJ leukemia_NN virus_NN reverse_NN transcriptase_NN (_( Clontech_NP ,_, Palo_NP Alto_NP ,_, Calif._NP )_) ;_: cytokine_JJ mRNA_NN expression_NN was_VBD normalized_VBN for_IN beta-actin_NN cDNA_NN content_NN by_IN semiquantitative_JJ PCR_NP (_( Clontech_NP )_) ._SENT Quantification_NN of_IN cytokine_NN cDNA_NN by_IN PCR_NP ._SENT |_SYM PCR_NP was_VBD performed_VBN in_IN 50_CD mul_NN of_IN reaction_NN mixture_NN containing_VBG 10_CD mul_NN of_IN RT_NP reaction_NN mixture_NN ,_, 1x_NP PCR_NP buffer_NN (_( 20_CD mM_NP Tris-HCl_NP ,_, 100_CD mM_NP KCl_NP ,_, 0.1_CD mM_NP EDTA_NP ,_, 1_CD mM_NP dithiothreitol_NN ,_, 0.5_CD %_NN Tween_NP 20_CD ,_, 0.5_CD %_NN Nonidet_NP P-40_NP ,_, 50_CD %_NN glycerol_NN )_) ,_, 200_CD mM_NP dNTPs_NNS ,_, 1.25_CD U_NP of_IN Taq_NP polymerase_NN (_( Takara_NP ,_, Otsu_NP ,_, Japan_NP )_) ,_, 0.4_CD mM_NP beta-actin_NN primers_NNS ,_, and_CC 0.4_CD mM_NNS (_( each_DT )_) cytokines_NNS ._SENT The_DT following_VBG primers_NNS were_VBD used_VBN :_: IL-4_NN 5_CD '_'' primer_NN ,_, 5'CGGCAATTTGACCACGGACACCCGTGCATA3_JJ '_'' ;_: IL-4_NN 3_CD '_'' primer_NN ,_, 5'ACGTACTCTGGTTGGCTTCCTTCACAGGACAG3_JJ '_'' ;_: IL-10_NP 5_CD '_POS primer_NN ,_, 5'AAGCTGAGAACCAAGACCCAGACATCAAGGCG3_JJ '_'' ;_: IL-10_NP 3_CD '_POS primer_NN ,_, 5'AGCTAT_NP CCCAGAGCCCCAGATCCGATTTTGG3_NP '_'' ;_: IFN-gamma_NP 5_CD '_POS primer_NN ,_, 5'GCATCGTTTTGGGTTCTCTTGGCTGTTACTGC3_JJ '_'' ;_: IFN-gamma_NP 3_CD '_POS primer_NN ,_, 5'CTCCTTTTTCGCTTCCCTGTTTTAGCTGCTGG3_JJ '_'' ;_: tumor_NN necrosis_NN factor_NN alpha_NN (_( TNF-alpha_NP )_) 5_CD '_POS primer_NN ,_, 5'GAGTGACAAGCCTGTAGCCCATGTTGTAGCA3_JJ '_'' ;_: TNF-alpha_NP 3_CD '_POS primer_NN ,_, 5'GCAATGATCCCAAAGTAGACCTGCCCAGACT3_JJ '_'' ;_: TNF-beta_NP 5_CD '_POS primer_NN ,_, 5'ATGACACCACCTGAACGTCTCTTC3_JJ '_'' ;_: TNF-beta_NP 3_CD '_POS primer_NN ,_, 5'GAAGGCTCCAAAGAAGACAGTACT3_NP '_POS ._SENT Thermal_JJ cycling_NN was_VBD performed_VBN in_IN a_DT Touchdown_NP Hybaid_NP apparatus_NN (_( Celbio_NP ,_, Milan_NP ,_, Italy_NP )_) as_RB follows_VBZ :_: initial_JJ denaturation_NN at_IN 95C_NN for_IN 10_CD min_NN ;_: 35_CD cycles_NNS of_IN denaturation_NN at_IN 95C_NN for_IN 30_CD s_NNS ,_, annealing_VBG at_IN 60C_JJ for_IN 30_CD s_NNS ,_, and_CC extension_NN at_IN 72C_NP for_IN 30_CD s_NNS ;_: and_CC a_DT final_JJ amplification_NN step_NN at_IN 72C_NP for_IN 10_CD min_NN ._SENT PCR_NP products_NNS were_VBD electrophoresed_VBN in_IN a_DT 10_CD %_NN acrylamide_NN gel_NN and_CC stained_VBN with_IN 0.5_CD mg_NN of_IN ethidium_NN bromide_NN per_IN ml_NN ;_: the_DT size_NN of_IN cDNA_NN products_NNS was_VBD determined_VBN by_IN comparison_NN to_TO a_DT DNA_NP size_NN marker_NN ,_, pbR322_JJ (_( Sigma_NP )_) ._SENT The_DT bands_NNS on_IN the_DT gels_NNS were_VBD scanned_VBN by_IN transmission_NN densitometry_NN to_TO quantify_VB relative_JJ levels_NNS of_IN gene_NN expression_NN ,_, and_CC the_DT areas_NNS of_IN the_DT peaks_NNS were_VBD calculated_VBN in_IN arbitrary_JJ units_NNS ._SENT To_TO evaluate_VB the_DT relative_JJ levels_NNS of_IN expression_NN of_IN the_DT target_NN genes_NNS in_IN RT-PCR_NP ,_, the_DT value_NN of_IN the_DT internal_JJ standard_NN (_( beta-actin_NN )_) was_VBD used_VBN as_IN the_DT baseline_JJ gene_NN expression_NN of_IN that_DT sample_NN ,_, and_CC the_DT relative_JJ value_NN was_VBD calculated_VBN for_IN the_DT target_NN genes_NNS amplified_VBN in_IN that_DT reaction_NN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Statistical_NP analysis_NN was_VBD based_VBN on_IN a_DT nonparametric_JJ Jonckheere-Terpstra_NP test_NN for_IN trends_NNS ._SENT Data_NNS were_VBD also_RB analyzed_VBN by_IN a_DT nonparametric_JJ Kruskal-Wallis_NP test_NN ;_: P_NN values_NNS were_VBD two_CD sided_VBN ._SENT Demographic_JJ profile_NN of_IN the_DT study_NN cohort_NN ._SENT |_SYM The_DT patients_NNS enrolled_VBN in_IN the_DT protocol_NN (_( 7_CD females_NNS and_CC 11_CD males_NNS )_) had_VBD a_DT mean_JJ age_NN of_IN 33.8_CD years_NNS ._SENT Four_NP had_VBD a_DT diagnosis_NN of_IN AIDS_NP in_IN their_PP$ past_JJ medical_JJ history_NN and_CC eight_CD had_VBD a_DT CD4+_NP cell_NN count_NN below_IN 200_CD cells/mul_NN at_IN the_DT baseline_NN ._SENT None_NN of_IN the_DT patients_NNS had_VBD been_VBN immunized_VBN with_IN candidate_NN HIV_NP vaccines_NNS ;_: patients_NNS had_VBD previously_RB received_VBN a_DT mean_NN of_IN 3.6_CD NRTI_NP and_CC 2_CD PI_NP ._SENT All_DT of_IN the_DT patients_NNS were_VBD tested_VBN at_IN the_DT time_NN points_NNS shown_VBN in_IN the_DT text_NN ._SENT CD4+_JJ cell_NN counts_NNS progressively_RB increased_VBN in_IN all_DT individuals_NNS after_IN the_DT initiation_NN of_IN therapy_NN ._SENT Thus_RB ,_, mean_VBP (_( range_NN )_) CD4_NP cell_NN counts_NNS were_VBD as_RB follows_VBZ :_: t0_NN ,_, 212_CD (_( 115-328_CD )_) CD4_NP cells/mul_NN ;_: t1_JJ ,_, 227_CD (_( 131-_CD 350_CD )_) CD4_NP cells/mul_NN ;_: t2_JJ ,_, 291_CD (_( 174-444_CD )_) CD4_NP cells/mul_NN ;_: t3_NN ,_, 399_CD (_( 312-497_CD )_) CD4_NP cells/mul_NN ._SENT The_DT change_NN was_VBD significant_JJ (_( P_NN =_SYM 0.011_CD )_) when_WRB the_DT baseline_JJ value_NN was_VBD compared_VBN with_IN the_DT value_NN observed_VBD after_IN 10_CD months_NNS of_IN therapy_NN (_( t3_NN )_) ._SENT HIV_NP genomic_JJ RNA_NP was_VBD detectable_JJ in_IN all_DT patients_NNS at_IN the_DT baseline_NN (_( mean_VB ,_, 109,217_CD ;_: range_NN ,_, 62,488-198,714_CD copies/mul_NN )_) and_CC decreased_VBD during_IN therapy_NN in_IN all_DT cases_NNS (_( t1_JJ mean_NN ,_, 104,100_CD ;_: range_NN ,_, 58,227-196,515_CD copies/mul_NN ;_: t2_JJ mean_NN ,_, 39,744_CD ;_: range_NN ,_, 21,057-74,480_CD copies/mul_NN ;_: t3_JJ mean_NN ,_, 11,518_CD ;_: range_NN ,_, 499_CD to_TO 15,511_CD copies/mul_NN )_) ._SENT HIV_NP RNA_NP at_IN t3_NN was_VBD undetectable_JJ for_IN 12_CD of_IN 18_CD subjects_NNS ._SENT A_DT trend_NN toward_IN a_DT greater_JJR increase_NN in_IN CD4_NP counts_NNS was_VBD seen_VBN in_IN the_DT 12_CD patients_NNS who_WP achieved_VBD suppression_NN of_IN plasma_NN viremia_NN below_IN the_DT limit_NN of_IN detection_NN ._SENT Modulation_NN of_IN immune_JJ functions_NNS ._SENT |_SYM Env-stimulated_JJ production_NN of_IN IL-2_NP and_CC IFN-gamma_NP was_VBD augmented_VBN whereas_IN IL-10_NP production_NN was_VBD reduced_VBN in_IN the_DT patients_NNS ._SENT These_DT results_NNS (_( means_NN +-_NN standard_NN errors_NNS )_) are_VBP shown_VBN in_IN Fig._NN ._SENT Thus_RB ,_, Env-stimulated_NP IL-2_NP and_CC IFN-gamma_NP production_NN was_VBD significantly_RB increased_VBN 2_CD months_NNS after_IN initiation_NN of_IN therapy_NN (_( t2_NN )_) ;_: the_DT increase_NN was_VBD still_RB observed_VBN at_IN t3_NN (_( P_NN <_SYM 0.01_CD in_IN all_DT cases_NNS )_) ._SENT IL-10_JJ production_NN was_VBD significantly_RB diminished_VBN at_IN the_DT last_JJ time_NN point_NN (_( t3_NP )_) (_( P_NN <_SYM 0.01_CD )_) ._SENT Mitogen-stimulated_JJ IL-2_NP production_NN was_VBD marginally_RB improved_VBN at_IN t3_NN ;_: the_DT production_NN of_IN both_DT IFN-gamma_NP and_CC IL-10_NP upon_IN mitogen_NN stimulation_NN was_VBD augmented_VBN ,_, albeit_IN not_RB significantly_RB ,_, at_IN t1_JJ and_CC t2_JJ and_CC returned_VBN to_TO baseline_NN by_IN the_DT end_NN of_IN the_DT study_NN period_NN ._SENT Modulation_NN of_IN cytokine_NN mRNA_NN ._SENT |_SYM Cytokine-specific_NP mRNA_NP was_VBD quantified_VBN in_IN resting_JJ PBMC_NN of_IN all_DT patients_NNS at_IN the_DT beginning_NN and_CC after_IN 10_CD months_NNS of_IN therapy_NN (_( cytokine_NN mRNA_NN could_MD not_RB be_VB examined_VBN at_IN t1_JJ and_CC t2_JJ because_IN of_IN limitations_NNS in_IN the_DT number_NN of_IN available_JJ PBMC_NN )_) ._SENT Because_IN TNF-alpha_NP exerts_VBZ a_DT direct_JJ effect_NN on_IN viral_JJ replication_NN and_CC TNF-beta_NP is_VBZ suggested_VBN to_TO be_VB a_DT mediator_NN of_IN apoptotic_JJ cell_NN death_NN in_IN HIV_NP infection_NN ,_, the_DT expression_NN of_IN these_DT two_CD cytokines_NNS was_VBD measured_VBN as_RB well_RB ._SENT Results_NNS showed_VBD that_IN after_IN 10_CD months_NNS of_IN therapy_NN ,_, (_( i_NP )_) the_DT expression_NN of_IN IFN-gamma_NP was_VBD higher_JJR and_CC (_( ii_NNS )_) the_DT expression_NN of_IN IL-10_NP ,_, IL-4_NN ,_, TNF-alpha_NP ,_, and_CC TNF-beta_NP was_VBD lower_JJR ._SENT IL-2_NP was_VBD not_RB detectable_JJ in_IN resting_VBG PBMC_NP (_( Fig._NN and_CC Table_NN )_) ._SENT FIG._NN 1_CD ._SENT |_SYM (_( A_NP )_) Env-stimulated_JJ cytokine_NN production_NN (_( IL-2_NP ,_, IFN-gamma_NP ,_, IL-4_NN ,_, and_CC IL-10_NP )_) by_IN PBMC_NP of_IN HIV-infected_JJ individuals_NNS at_IN different_JJ time_NN points_NNS (_( before_IN treatment_NN [_SYM t0_NN ]_SYM and_CC 2_CD weeks_NNS [_SYM t1_NN ]_SYM ,_, 2_CD months_NNS [_SYM t2_NN ]_SYM ,_, and_CC 10_CD months_NNS [_SYM t3_NN ]_SYM into_IN therapy_NN )_) ._SENT (_( A_NP )_) Env-stimulated_JJ cytokine_NN production_NN (_( IL-2_NP ,_, IFN-gamma_NP ,_, IL-4_NN ,_, and_CC IL-10_NP )_) by_IN PBMC_NP of_IN HIV-infected_JJ individuals_NNS at_IN different_JJ time_NN points_NNS (_( before_IN treatment_NN [_SYM t0_NN ]_SYM and_CC 2_CD weeks_NNS [_SYM t1_NN ]_SYM ,_, 2_CD months_NNS [_SYM t2_NN ]_SYM ,_, and_CC 10_CD months_NNS [_SYM t3_NN ]_SYM into_IN therapy_NN )_) ._SENT The_DT results_NNS are_VBP shown_VBN as_IN means_NN +-_NN standard_NN errors_NNS ._SENT (_( B_LS )_) PHA-stimulated_JJ production_NN of_IN the_DT same_JJ cytokines_NNS ._SENT *_SYM ,_, values_NNS are_VBP significantly_RB different_JJ from_IN those_DT at_IN t0_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Quantification_NN of_IN mRNA_NN for_IN IL-4_NN ,_, IL-10_NP ,_, IFN-gamma_NP ,_, TNF-alpha_NP ,_, and_CC TNF-beta_NP in_IN resting_VBG PBMC_NP of_IN one_CD representative_NN HIV-infected_JJ individual_NN before_IN (_( t0_NN )_) and_CC after_IN 10_CD months_NNS of_IN (_( t3_NN )_) therapy_NN ._SENT Quantification_NN of_IN mRNA_NN for_IN IL-4_NN ,_, IL-10_NP ,_, IFN-gamma_NP ,_, TNF-alpha_NP ,_, and_CC TNF-beta_NP in_IN resting_VBG PBMC_NP of_IN one_CD representative_NN HIV-infected_JJ individual_NN before_IN (_( t0_NN )_) and_CC after_IN 10_CD months_NNS of_IN (_( t3_NN )_) therapy_NN ._SENT The_DT upper_JJ bands_NNS show_VBP cDNA_NN retrotranscribed_NN from_IN cytokine_NN mRNA_NN extracted_VBN from_IN patient_JJ PBMC_NP ;_: the_DT lower_JJR bands_NNS show_VBP cDNA_NN retrotranscribed_NN from_IN beta-actin_NN mRNA_NN extracted_VBN from_IN patient_JJ PBMC_NP and_CC used_VBN to_TO normalize_VB the_DT PCRs_NN ._SENT TABLE_NN 1_CD |_SYM Cytokine-specific_JJ mRNA_NN in_IN HIV-infected_JJ patients_NNS undergoing_VBG a_DT rescue_NN therapy_NN The_DT activities_NNS of_IN an_DT EFV-_NP ,_, NFV-_NP ,_, and_CC d4T-based_JJ therapy_NN on_IN immunologic_JJ and_CC virologic_JJ parameters_NNS were_VBD evaluated_VBN by_IN analyzing_VBG the_DT effects_NNS of_IN this_DT association_NN in_IN 18_CD randomly_RB selected_VBN ,_, HIV-infected_JJ ,_, heavily_RB pretreated_JJ individuals_NNS who_WP failed_VBD previous_JJ therapeutic_JJ regimens_NNS ._SENT The_DT combination_NN was_VBD well_RB tolerated_VBN ,_, resulted_VBN in_IN increased_VBN CD4_NP cell_NN counts_NNS and_CC reduced_VBN HIV_NP plasma_NN viremia_NN ,_, and_CC at_IN the_DT same_JJ time_NN induced_VBD a_DT positive_JJ trend_NN in_IN HIV-specific_NP type_NN 1_CD cytokine_NN production_NN as_RB well_RB as_IN a_DT significant_JJ reduction_NN in_IN the_DT generation_NN of_IN IL-10_NP ._SENT To_TO verify_VB if_IN the_DT variations_NNS in_IN cytokine_NN production_NN were_VBD secondary_JJ to_TO modifications_NNS in_IN their_PP$ patterns_NNS of_IN expression_NN ,_, the_DT amount_NN of_IN cytokine-specific_JJ mRNA_NN was_VBD analyzed_VBN in_IN resting_JJ PBMC_NP ._SENT The_DT results_NNS showed_VBD that_IN IFN-gamma_NP mRNA_NP was_VBD more_RBR abundant_JJ while_IN IL-10_NP and_CC IL-4_NN mRNAs_NNS were_VBD expressed_VBN less_JJR after_IN 10_CD months_NNS of_IN therapy_NN ._SENT Because_IN the_DT generation_NN of_IN type_NN 1_CD and_CC type_NN 2_CD cytokines_NNS is_VBZ cross-regulatory_JJ ,_, it_PP is_VBZ not_RB surprising_JJ that_IN during_IN follow-up_NN the_DT decreased_VBN expression_NN and_CC production_NN of_IN IL-10_NP coincided_VBD with_IN an_DT augmented_JJ generation_NN of_IN IL-2_NP and_CC IFN-gamma_NP ._SENT Env-stimulated_NP IL-2_NP and_CC IFN-gamma_NP production_NN increased_VBD before_IN down_RB modulation_NN of_IN IL-10_NP production_NN could_MD be_VB observed_VBN ._SENT A_DT speculative_JJ hypothesis_NN could_MD be_VB that_IN the_DT drug_NN regimen_NN studied_VBD here_RB preferentially_RB stimulates_VBZ type_NN 1_CD cytokine_NN production_NN and_CC that_IN the_DT increase_NN of_IN these_DT cytokines_NNS results_NNS in_IN the_DT subsequent_JJ cross-regulation_NN of_IN IL-10_NP production_NN ._SENT TNF-alpha_NP expression_NN was_VBD reduced_VBN in_IN this_DT study_NN ._SENT Because_IN TNF-alpha_NP directly_RB stimulates_VBZ viral_JJ replication_NN ,_, the_DT modulation_NN of_IN this_DT cytokine_NN could_MD contribute_VB to_TO the_DT reduction_NN of_IN HIV_NP viral_JJ load_NN observed_VBD in_IN our_PP$ patients_NNS ._SENT CD4_JJ cell_NN counts_NNS progressively_RB improved_VBN concomitantly_RB with_IN a_DT reduction_NN of_IN TNF-beta_NP expression_NN in_IN the_DT study_NN presented_VBD here_RB ._SENT Because_IN TNF-beta_NP is_VBZ known_VBN to_TO be_VB a_DT mediator_NN of_IN apoptotic_JJ cell_NN death_NN in_IN HIV_NP infection_NN it_PP is_VBZ tempting_JJ to_TO speculate_VB that_IN increases_NNS in_IN CD4_NP counts_NNS are_VBP at_IN least_JJS partially_RB secondary_JJ to_TO a_DT reduced_VBN susceptibility_NN of_IN CD4_NP cells_NNS to_TO apoptosis_NN ._SENT The_DT analysis_NN of_IN the_DT efficacy_NN data_NNS relative_JJ to_TO the_DT entire_JJ cohort_NN of_IN patients_NNS showed_VBD that_IN plasma_NN viral_JJ load_NN was_VBD reduced_VBN by_IN 1.7_CD log_NN at_IN 12_CD months_NNS with_IN a_DT sustained_JJ increase_NN in_IN CD4+-T-cell_NN count_NN ._SENT HIV_NP plasma_NN viremia_NN was_VBD undetectable_JJ in_IN 12_CD of_IN the_DT 18_CD patients_NNS after_IN 1_CD year_NN of_IN therapy_NN ._SENT In_IN light_NN of_IN recent_JJ data_NNS suggesting_VBG that_DT HIV-specific_JJ T-cell_NN function_NN would_MD not_RB be_VB recovered_VBN in_IN patients_NNS with_IN fully_RB suppressed_VBN viral_JJ replication_NN (_( reviewed_VBN in_IN reference_NN )_) ,_, we_PP compared_VBD Env-specific_JJ cytokine_NN production_NN in_IN patients_NNS in_IN whom_WP viremia_NNS was_VBD or_CC was_VBD not_RB still_RB detectable_JJ after_IN therapy_NN ._SENT We_PP did_VBD not_RB observe_VB any_DT correlation_NN between_IN residual_JJ viremia_NN and_CC improvement_NN in_IN immune_JJ function_NN ._SENT This_DT result_NN can_MD probably_RB be_VB explained_VBN considering_VBG the_DT small_JJ number_NN of_IN individuals_NNS studied_VBN and_CC the_DT fact_NN that_IN our_PP$ patients_NNS had_VBD advanced_JJ illness_NN and_CC had_VBD failed_VBN previous_JJ combination_NN therapies_NNS ._SENT It_PP is_VBZ interesting_JJ to_TO observe_VB that_DT modulation_NN of_IN HIV-specific_JJ immune_JJ responses_NNS was_VBD detected_VBN in_IN our_PP$ patients_NNS within_IN a_DT few_JJ months_NNS ._SENT These_DT results_NNS contrast_NN with_IN recent_JJ data_NNS showing_VBG that_DT improvement_NN in_IN HIV-specific_JJ immunity_NN may_MD not_RB be_VB seen_VBN in_IN the_DT first_JJ year_NN of_IN antiviral_JJ therapy_NN ._SENT The_DT discrepancy_NN could_MD be_VB secondary_JJ to_TO the_DT fact_NN that_IN ,_, whereas_IN we_PP measured_VBD Env-specific_JJ responses_NNS ,_, Angel_NP et_FW al._FW and_CC Blankson_NN et_FW al._FW stimulated_VBN PBMC_NP with_IN Gag_NP or_CC Pol_NP ._SENT Numerous_JJ studies_NNS showed_VBD that_IN HAART_NP positively_RB influences_VBZ quantitative_JJ and_CC qualitative_JJ immune_JJ parameters_NNS in_IN both_DT acute_JJ and_CC chronic_JJ HIV_NP infection_NN ,_, but_CC the_DT immune_JJ reconstitution_NN that_WDT ensues_VBZ nevertheless_RB is_VBZ never_RB complete_JJ ._SENT Thus_RB ,_, triple_JJ therapy_NN is_VBZ associated_VBN with_IN improvement_NN in_IN CD4_NP counts_NNS and_CC functions_NNS that_WDT are_VBP more_JJR easily_RB seen_VBN in_IN early-_NN than_IN in_IN late-stage_NN patients_NNS (_( ,_, ,_, ,_, ,_, ,_, ,_, ,_, ,_, ,_, ,_, ,_, ;_: M._NP Albrecht_NP ,_, D._NP Katzenstein_NP ,_, R._NP Bosch_NP ,_, and_CC S._NP Liou_NP ,_, Abstr_NP ._SENT 7th_JJ Conf_NP ._SENT Retrovir_NP ._SENT Opportunistic_JJ Infect_NNS ._SENT ,_, abstr_NN ._SENT 531_CD ,_, 2000_CD )_) ._SENT Our_PP$ data_NNS show_VBP that_IN partial_JJ modulation_NN of_IN immune_JJ functions_NNS in_IN chronic_JJ HIV_NP infection_NN can_MD be_VB seen_VBN even_RB in_IN patients_NNS who_WP had_VBD previously_RB failed_VBN multiple_JJ regimens_NNS ._SENT NNRTIs_NP ,_, in_IN addition_NN to_TO NRTIs_NP and_CC PIs_NP ,_, have_VBP gained_VBN a_DT definite_JJ place_NN in_IN the_DT treatment_NN of_IN HIV-1_JJ infection_NN (_( reviewed_VBN in_IN references_NNS ,_, ,_, ,_, and_CC )_) ._SENT EFV_NP is_VBZ an_DT NNRTI_NP which_WDT is_VBZ used_VBN in_IN combination_NN with_IN other_JJ antiviral_JJ compounds_NNS in_IN the_DT treatment_NN of_IN HIV_NP infection_NN and_CC is_VBZ shown_VBN to_TO knock_VB out_RP virus_NN replication_NN and_CC to_TO delay_VB virus_NN resistance_NN from_IN arising_VBG (_( ;_: Albrecht_NP et_FW al._FW ,_, 7th_JJ Conf_NP ._SENT Retrovir_NP ._SENT Opportunistic_JJ Infect_NNS ._SENT )_) ._SENT Treatment_NN guidelines_NNS were_VBD recently_RB modified_VBN to_TO include_VB NNRTI_NP as_IN an_DT acceptable_JJ substitute_NN for_IN a_DT PI_NP in_IN primary_JJ therapy_NN ._SENT Results_NNS stemming_VBG from_IN a_DT number_NN of_IN protocols_NNS in_IN which_WDT this_DT therapeutic_JJ approach_NN was_VBD used_VBN in_IN HIV-infected_JJ individuals_NNS confirmed_VBD that_IN NNRTI-including_NP regimens_NNS are_VBP capable_JJ of_IN achieving_VBG a_DT very_RB consistent_JJ suppression_NN of_IN HIV_NP plasma_NN viremia_NN ._SENT For_IN the_DT 006_CD study_NN participants_NNS were_VBD randomized_VBN to_TO receive_VB EFV_NP in_IN association_NN either_CC with_IN nucleoside_NN analogues_NNS or_CC with_IN PIs_NP ._SENT The_DT results_NNS showed_VBD that_DT suppression_NN of_IN plasma_NN HIV-1_NP RNA_NP to_TO undetectable_JJ levels_NNS was_VBD achieved_VBN in_IN a_DT higher_JJR percentage_NN of_IN patients_NNS in_IN the_DT NNRTI_NP plus_CC nucleoside_NN analogues_NNS group_NN than_IN in_IN the_DT PI_NP plus_CC nucleoside_NN analogues_NNS group_NN ._SENT In_IN the_DT ACTG_NP 302_CD study_NN NNRTI-_NN and_CC PI-naive_JJ patients_NNS who_WP had_VBD previously_RB failed_VBN an_DT NRTI_NP therapy_NN were_VBD randomized_VBN to_TO receive_VB EFV_NP ,_, NFV_NP ,_, or_CC both_DT drugs_NNS in_IN combination_NN to_TO 1_CD or_CC 2_CD NRTIs_NP ._SENT By_IN week_NN 40_CD the_DT percentage_NN of_IN individuals_NNS with_IN a_DT viral_JJ load_NN below_IN the_DT detection_NN limit_NN was_VBD significantly_RB higher_JJR in_IN the_DT EFV-_NN than_IN in_IN the_DT NFV-based_JJ arms_NNS (_( Albrecht_NP et_FW al._FW ,_, 7th_JJ Conf_NP ._SENT Retrovir_NP ._SENT Opportunistic_JJ Infect_NNS ._SENT )_) ._SENT Finally_RB ,_, recent_JJ data_NNS comparing_VBG the_DT virologic_JJ effect_NN of_IN NNRTI-_NP and_CC PI-based_JJ antiretroviral_JJ combinations_NNS suggest_VBP that_IN the_DT use_NN of_IN NNRTI_NP is_VBZ associated_VBN with_IN a_DT faster_JJR and_CC more_JJR frequent_JJ initial_JJ virologic_JJ response_NN ._SENT In_IN conclusion_NN ,_, our_PP$ results_NNS suggest_VBP that_IN NNRTI-employing_JJ antiviral_JJ therapies_NNS could_MD be_VB useful_JJ as_IN a_DT rescue_NN regimen_NN in_IN advanced_JJ cases_NNS of_IN HIV_NP infection_NN ._SENT Because_IN these_DT data_NNS are_VBP based_VBN on_IN a_DT small_JJ group_NN of_IN patients_NNS and_CC because_IN the_DT design_NN of_IN this_DT preliminary_JJ study_NN did_VBD not_RB involve_VB a_DT control_NN arm_NN ,_, further_JJR studies_NNS will_MD be_VB necessary_JJ to_TO clarify_VB the_DT best_JJS way_NN to_TO utilize_VB this_DT strategy_NN in_IN advanced_JJ HIV_NP disease_NN ._SENT 